Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.68 |
| ▸ | NOD1 | Q9Y239 | 8/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19034944 | 1.00 | GLP1R (0.68) | GLP1RNOD1FOLH1 | |
| SCHEMBL19034930 | 1.00 | GLP1R (0.68) | GLP1RNOD1FOLH1 | |
| SCHEMBL15537317 | 1.00 | GLP1R (0.68) | GLP1RNOD1FOLH1 | |
| SCHEMBL24249859 | 1.00 | GLP1R (0.68) | GLP1RNOD1FOLH1 | |
| SCHEMBL21110472 | 1.00 | GLP1R (0.68) | GLP1RNOD1FOLH1 | |
| SCHEMBL24249840 | 1.00 | GLP1R (0.68) | GLP1RNOD1FOLH1 | |
| SCHEMBL13694019 | 1.00 | GLP1R (0.68) | GLP1RNOD1FOLH1 | |
| SCHEMBL19034796 | 1.00 | GLP1R (0.68) | GLP1RNOD1FOLH1 | |
| SCHEMBL1758670 | 1.00 | GLP1R (0.68) | GLP1RNOD1FOLH1 | |
| SCHEMBL29322995 | 1.00 | GLP1R (0.68) | GLP1RNOD1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3110840-B1 | AN A22K, DESB27, B29R, DES B30, AT EPSILON POSITION OF LYSINE 22 ACYLATED HUMAN INSULIN ANALOGUE | NOVO NORDISK AS (DK) | 2020-10-21 | — | — | EP | disclosed |
| US-10040839-B2 | Insulin derivatives and the medical uses hereof | NOVO NORDISK A/S (DK) | 2018-08-07 | — | — | US | disclosed |
| WO-2017032795-A1 | NOVEL INSULIN DERIVATIVES AND THE MEDICAL USES HEREOF | NOVO NORDISK A/S (DK) | 2017-03-02 | — | — | WO | disclosed |
| WO-2017032797-A1 | NOVEL INSULIN DERIVATIVES AND THE MEDICAL USES HEREOF | NOVO NORDISK A/S (DK) | 2017-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10040839-B2 | Insulin derivatives and the medical uses hereof | IAPP, INSR, IRS1 | GLP1R 9/4885NOD1 2706/4885FOLH1 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.